AMNEAL PHARMACEUTICALS INC (AMRX) Stock Fundamental Analysis
USA - NASDAQ:AMRX - US03168L1052 - Common Stock
11.64 USD
+0.12 (+1.04%)
11.76 USD
+0.12 (+1.03%)
We assign a fundamental rating of 5 out of 10 to AMRX. AMRX was compared to 192 industry peers in the Pharmaceuticals industry. While AMRX is still in line with the averages on profitability rating, there are concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on AMRX.
1. Profitability
1.1 Basic Checks
In the past year AMRX was profitable.
In the past year AMRX had a positive cash flow from operations.
In multiple years AMRX reported negative net income over the last 5 years.
Each year in the past 5 years AMRX had a positive operating cash flow.
1.2 Ratios
AMRX's Return On Assets of 0.16% is fine compared to the rest of the industry. AMRX outperforms 79.17% of its industry peers.
The Return On Invested Capital of AMRX (10.43%) is better than 89.06% of its industry peers.
The Average Return On Invested Capital over the past 3 years for AMRX is significantly below the industry average of 13.75%.
The last Return On Invested Capital (10.43%) for AMRX is above the 3 year average (7.98%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.16% | ||
| ROE | N/A | ||
| ROIC | 10.43% |
ROA(3y)-3.06%
ROA(5y)-1.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)7.98%
ROIC(5y)6.53%
1.3 Margins
AMRX has a Profit Margin of 0.20%. This is in the better half of the industry: AMRX outperforms 79.17% of its industry peers.
AMRX's Operating Margin of 12.32% is amongst the best of the industry. AMRX outperforms 84.90% of its industry peers.
AMRX's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 36.76%, AMRX is in line with its industry, outperforming 58.85% of the companies in the same industry.
AMRX's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.32% | ||
| PM (TTM) | 0.2% | ||
| GM | 36.76% |
OM growth 3Y6.45%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y4.39%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so AMRX is still creating some value.
Compared to 1 year ago, AMRX has less shares outstanding
Compared to 5 years ago, AMRX has more shares outstanding
The debt/assets ratio for AMRX has been reduced compared to a year ago.
2.2 Solvency
AMRX has a debt to FCF ratio of 11.13. This is a negative value and a sign of low solvency as AMRX would need 11.13 years to pay back of all of its debts.
AMRX has a Debt to FCF ratio of 11.13. This is in the better half of the industry: AMRX outperforms 77.08% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 11.13 | ||
| Altman-Z | N/A |
ROIC/WACC1.04
WACC10.01%
2.3 Liquidity
A Current Ratio of 2.13 indicates that AMRX has no problem at all paying its short term obligations.
AMRX has a Current ratio of 2.13. This is in the lower half of the industry: AMRX underperforms 61.46% of its industry peers.
A Quick Ratio of 1.42 indicates that AMRX should not have too much problems paying its short term obligations.
AMRX has a Quick ratio of 1.42. This is in the lower half of the industry: AMRX underperforms 65.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.13 | ||
| Quick Ratio | 1.42 |
3. Growth
3.1 Past
AMRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.00%, which is quite impressive.
AMRX shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 10.63% yearly.
AMRX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 16.73%.
AMRX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.43% yearly.
EPS 1Y (TTM)25%
EPS 3Y-11.61%
EPS 5Y10.63%
EPS Q2Q%6.25%
Revenue 1Y (TTM)16.73%
Revenue growth 3Y10.1%
Revenue growth 5Y11.43%
Sales Q2Q%11.68%
3.2 Future
Based on estimates for the next years, AMRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.95% on average per year.
The Revenue is expected to grow by 0.60% on average over the next years.
EPS Next Y42.89%
EPS Next 2Y29.93%
EPS Next 3Y24.73%
EPS Next 5Y11.95%
Revenue Next Year8.95%
Revenue Next 2Y7.95%
Revenue Next 3Y7.63%
Revenue Next 5Y0.6%
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 15.52, which indicates a correct valuation of AMRX.
Based on the Price/Earnings ratio, AMRX is valued cheaply inside the industry as 85.94% of the companies are valued more expensively.
AMRX's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 25.89.
The Price/Forward Earnings ratio is 11.89, which indicates a very decent valuation of AMRX.
AMRX's Price/Forward Earnings ratio is rather cheap when compared to the industry. AMRX is cheaper than 85.42% of the companies in the same industry.
AMRX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 34.59.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.52 | ||
| Fwd PE | 11.89 |
4.2 Price Multiples
AMRX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. AMRX is cheaper than 86.98% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of AMRX indicates a rather cheap valuation: AMRX is cheaper than 85.94% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 15.46 | ||
| EV/EBITDA | 10.11 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of AMRX may justify a higher PE ratio.
A more expensive valuation may be justified as AMRX's earnings are expected to grow with 24.73% in the coming years.
PEG (NY)0.36
PEG (5Y)1.46
EPS Next 2Y29.93%
EPS Next 3Y24.73%
5. Dividend
5.1 Amount
No dividends for AMRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
11.64
+0.12 (+1.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners41.99%
Inst Owner Change5.09%
Ins Owners46.35%
Ins Owner Change-17.01%
Market Cap3.66B
Revenue(TTM)2.93B
Net Income(TTM)5.90M
Analysts82
Price Target12.24 (5.15%)
Short Float %3.69%
Short Ratio3.75
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.63%
Min EPS beat(2)21.21%
Max EPS beat(2)40.06%
EPS beat(4)3
Avg EPS beat(4)19.7%
Min EPS beat(4)-22.85%
Max EPS beat(4)40.37%
EPS beat(8)7
Avg EPS beat(8)26.2%
EPS beat(12)11
Avg EPS beat(12)30.21%
EPS beat(16)11
Avg EPS beat(16)19.73%
Revenue beat(2)0
Avg Revenue beat(2)-2.51%
Min Revenue beat(2)-4.6%
Max Revenue beat(2)-0.41%
Revenue beat(4)1
Avg Revenue beat(4)-2.13%
Min Revenue beat(4)-4.71%
Max Revenue beat(4)1.22%
Revenue beat(8)3
Avg Revenue beat(8)-0.67%
Revenue beat(12)7
Avg Revenue beat(12)0.45%
Revenue beat(16)8
Avg Revenue beat(16)-0.15%
PT rev (1m)0%
PT rev (3m)2.13%
EPS NQ rev (1m)10.77%
EPS NQ rev (3m)18.03%
EPS NY rev (1m)5.86%
EPS NY rev (3m)15.25%
Revenue NQ rev (1m)-0.58%
Revenue NQ rev (3m)-0.58%
Revenue NY rev (1m)0.62%
Revenue NY rev (3m)0.26%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.52 | ||
| Fwd PE | 11.89 | ||
| P/S | 1.25 | ||
| P/FCF | 15.46 | ||
| P/OCF | 11.15 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.11 |
EPS(TTM)0.75
EY6.44%
EPS(NY)0.98
Fwd EY8.41%
FCF(TTM)0.75
FCFY6.47%
OCF(TTM)1.04
OCFY8.97%
SpS9.34
BVpS-0.35
TBVpS-4.12
PEG (NY)0.36
PEG (5Y)1.46
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.16% | ||
| ROE | N/A | ||
| ROCE | 13.2% | ||
| ROIC | 10.43% | ||
| ROICexc | 11.26% | ||
| ROICexgc | 21.11% | ||
| OM | 12.32% | ||
| PM (TTM) | 0.2% | ||
| GM | 36.76% | ||
| FCFM | 8.06% |
ROA(3y)-3.06%
ROA(5y)-1.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)7.98%
ROIC(5y)6.53%
ROICexc(3y)8.26%
ROICexc(5y)6.86%
ROICexgc(3y)18.59%
ROICexgc(5y)15.87%
ROCE(3y)10.57%
ROCE(5y)8.54%
ROICexgc growth 3Y25.12%
ROICexgc growth 5YN/A
ROICexc growth 3Y27.15%
ROICexc growth 5YN/A
OM growth 3Y6.45%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y4.39%
F-Score7
Asset Turnover0.82
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 11.13 | ||
| Debt/EBITDA | 4.36 | ||
| Cap/Depr | 37.95% | ||
| Cap/Sales | 3.11% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 54.45% | ||
| Profit Quality | 4008.53% | ||
| Current Ratio | 2.13 | ||
| Quick Ratio | 1.42 | ||
| Altman-Z | N/A |
F-Score7
WACC10.01%
ROIC/WACC1.04
Cap/Depr(3y)33.21%
Cap/Depr(5y)30.06%
Cap/Sales(3y)3.22%
Cap/Sales(5y)3.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25%
EPS 3Y-11.61%
EPS 5Y10.63%
EPS Q2Q%6.25%
EPS Next Y42.89%
EPS Next 2Y29.93%
EPS Next 3Y24.73%
EPS Next 5Y11.95%
Revenue 1Y (TTM)16.73%
Revenue growth 3Y10.1%
Revenue growth 5Y11.43%
Sales Q2Q%11.68%
Revenue Next Year8.95%
Revenue Next 2Y7.95%
Revenue Next 3Y7.63%
Revenue Next 5Y0.6%
EBIT growth 1Y26.75%
EBIT growth 3Y17.2%
EBIT growth 5YN/A
EBIT Next Year13.84%
EBIT Next 3Y10.27%
EBIT Next 5Y3.87%
FCF growth 1Y72%
FCF growth 3Y5.18%
FCF growth 5YN/A
OCF growth 1Y75.78%
OCF growth 3Y6.86%
OCF growth 5Y180.48%
AMNEAL PHARMACEUTICALS INC / AMRX FAQ
What is the fundamental rating for AMRX stock?
ChartMill assigns a fundamental rating of 5 / 10 to AMRX.
What is the valuation status of AMNEAL PHARMACEUTICALS INC (AMRX) stock?
ChartMill assigns a valuation rating of 8 / 10 to AMNEAL PHARMACEUTICALS INC (AMRX). This can be considered as Undervalued.
How profitable is AMNEAL PHARMACEUTICALS INC (AMRX) stock?
AMNEAL PHARMACEUTICALS INC (AMRX) has a profitability rating of 6 / 10.
What is the financial health of AMNEAL PHARMACEUTICALS INC (AMRX) stock?
The financial health rating of AMNEAL PHARMACEUTICALS INC (AMRX) is 3 / 10.
What is the earnings growth outlook for AMNEAL PHARMACEUTICALS INC?
The Earnings per Share (EPS) of AMNEAL PHARMACEUTICALS INC (AMRX) is expected to grow by 42.89% in the next year.